Moderna and Merck announced positive Phase 3 trial results for a personalized mRNA-based cancer vaccine combined with immunotherapy in treating melanoma, preventing recurrence and spread of skin cancer. The vaccine, called INTerpath001, showed efficacy in late-stage trials and caused stock prices of both companies to surge on August 19, 2026.
No BS check run yet — press ⚖ to extract this story's claims and verify them against independent sources.
Combining a vaccine and immunotherapy approach could open new ways to treat cancer.
this outlet adds: defund, transfer, money, research, based
this outlet adds: time, article, 2026, based
Moderna and Merck shares soared on Wednesday after the companies said a personalized mRNA treatment hit its target of preventing skin cancer from recurring or spreading in a late-stage clinical trial. Why it matters: The results come at a pivotal moment for Moderna and mRNA research, after Trump administration health officials cut federal funding for new vaccines and asserted the technology poses
Melanoma is the most aggressive form of skin cancer causing about 2,600 deaths a year in the UK
New mRNA vaccine could reduce the recurrence and spread of skin cancer : NPR share.google/DfGNMsOgp7tA... Merck and Moderna announced a successful late-stage trial for a melanoma vaccine. NPR's Leila Fadel talks to Dr. Robert Vonderheide of Penn Medicine and the American Association for Cancer Research.
www.youtube.com/live/dUJj9zj... YouTube video by Kim Iversen
this outlet adds: want, credible, wouldn, plead, bailout, freemasons, watch, dqha
#skincancer #MSD #Moderna #mRNA #cancervaccine #skincancervaccine #mRNA #individualisedneoantigentherapy#melanoma #mRNAbasedcancervaccine #INTerpath001trial #immunotherapy #Individualisedneoantigentherapies #personalisedvaccine #cancerimmunotherapy #personalisedcancervaccines zurl.co/1Dq4A Strong phase 3 results for Moderna's individualised skin cancer vaccine could pave the way for a leap forward